APOB and atherosclerosis: As expected, genetic inhibition of PCSK9 was associated with lower levels of LDL-C and ApoB, less subclinical atherosclerosis, lower risk of MOVE, including ischaemic stroke, and directionally concordant effects on risk of FOVE and MCE.